



→ Cortney Inman

Associate

2099 Pennsylvania Avenue, N.W.
Suite 100
Washington, DC 20006-6801

T: +1.202.747.1869

F: +1.202.747.1901

cinman@sheppardmullin.com

Cortney Inman is an associate in the Governmental Practice Group in the firm's Washington, D.C. office and a member of the FDA Regulatory and Life Sciences teams.

Areas of Practice

Cortney's practice focuses on FDA regulatory matters, counseling clients in the life sciences industry with respect to a wide range of regulatory and compliance matters. She has advised life sciences companies on a variety of federal and state laws as it relates to the advertising, promotion, and distribution of FDA-regulated products. Cortney has also reviewed and developed policies and procedures in advancement of comprehensive compliance programs, investigated and responded to FDA 483 violations, and advised on varying transactions and agreements related to the commercialization and distribution of drug products. She is also a member of the firm's Women in Healthcare Leadership Collaborative, whose goal is to promote the advancement of women in the healthcare industry.

While attending the University of Virginia School of Law, Cortney served as Articles Editor for the *Virginia Law & Business Review*. In her third year, she was also selected to serve as a Legal Writing Fellow, assisting first-year law students learning legal research, writing, and advocacy. Cortney holds a B.A. in Philosophy from Virginia Commonwealth University, where she graduated *summa cum laude* and as a member of *Phi Kappa Phi* Honor Society.

Honors

Gardner Gillespie Environmental Pro Bono Award, 2024

Articles

- 2025 Top-of-Mind Issues for Life Sciences Companies
01.31.2025
- Key Takeaways From FDA's Latest Social Media Warnings
Law360, 12.03.2024
- FDA Warning Indicates Scrutiny Of Regenerative Health Cos.
Law360, 06.06.2024
- 2024 Top-of-Mind Issues for Life Sciences Companies
01.25.2024

- HHS Advisory Opinion Serves As Free Drug Program Guide
Law360, 03.20.2023
- 2023 Top-of-Mind Issues for Life Sciences Companies
01.11.2023

FDA Law Blog Posts

- "FDA Unleashes Wave of Enforcement: The Industry Faces a Crackdown on Drug Advertising," September 19, 2025
- "Key Takeaways from FDA's Latest Social Media Warnings," December 5, 2024
- "Ubrelyv Untitled Letter – A Double Fault for AbbVie? Or Makeup Misread for FDA?," September 17, 2024
- "Krazati Untitled Letter: A Cautionary Tale for CFL Promotion of Accelerated Approval Drugs," August 14, 2024
- "FDA Gets Technical on HCT/P Rules in Warning Letter to Human Tissue Company," May 31, 2024
- "FDA's Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI®," February 2, 2024
- "2024 Top-of-Mind Issues for Life Sciences Companies," January 25, 2024
- "FDA's Office of Prescription Drug Promotion Issues Second Untitled Letter of the Year to Exeltis for Misleading Statements Relating to SLYND®," August 25, 2023
- "FDA Releases Final Guidance on Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements," July 14, 2023
- "FDA Issues Proposed Rule for Standardized and Accessible Patient Medication Information," June 13, 2023
- "FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023," June 2, 2023
- "OIG Advisory Opinion Alert: Medical Flights for Patient Access," March 7, 2023

Events

2025 FDLI Annual Conference
Washington, DC, May 15-16, 2025

2023 FDLI Annual Conference
May 17-18, 2023

Practices

Governmental

FDA Regulatory

Women in Healthcare Leadership Collaborative

Industries

Life Sciences

Education

J.D., University of Virginia School of Law, 2022

B.A., Virginia Commonwealth University, 2018, *summa cum laude*, Phi Kappa Phi Honor Society

Admissions

District of Columbia

Maryland